Depressive Disorder
Pipeline by Development Stage
Drug Modality Breakdown
On Market (1)
Approved therapies currently available
Competitive Landscape
15 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
Showing 15 of 50 trials with date data
Clinical Trials (50)
Total enrollment: 75,036 patients across 50 trials
Efficacy and Safety of Paroxetine Controlled Release for Major Depressive Disorder in Irritable Bowel Syndrome Patients
Escitalopram in Depressive Patients With Acute Coronary Artery Syndrome
A Comparison of Tolerability and Efficacy of Different Doses of Duloxetine for the Treatment of Major Depressive Disorder
A Study of Duloxetine (LY248686) in the Treatment of Japanese Children and Adolescents With Depressive Disorder
A Study of Duloxetine (LY248686) in Japanese Children and Adolescents With Depressive Disorder
A Study of Flexible-dose Brexpiprazole as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder, the Delphinus Trial
Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial)
Study of the Safety and Efficacy of Fixed Dose OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Pyxis Trial)
Study of the Safety and Efficacy of Two Fixed Doses of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Polaris Trial)
An Eight-week Study of Saredutant and Paroxetine as Combination Treatment for Major Depressive Disorder
An Eight-week Study of Saredutant and Escitalopram as Combination Treatment for Major Depressive Disorder
A Study Evaluating the Safety and Tolerability of Abrupt Discontinuation of Saredutant in Patients With Depression
An Eight-week Study Evaluating the Efficacy of a 100mg Dose of Saredutant Once Daily, in Elderly Patients With Major Depressive Disorder
A North-American Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Generalized Anxiety Disorder
An Eight-week Study to Evaluate the Efficacy and Safety of 2 Doses of Saredutant in Patients With Generalized Anxiety Disorder
A 24-52-week Study to Evaluate the Long-term Efficacy and Safety of Saredutant in Patients With Depression (MAGENTA)
A Fifty-two-week Study to Evaluate the Safety of Saredutant in Adult and Elderly Patients With Depression
An Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Depression
An Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Depression
An Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Depression
An Eight-Week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Depression
Duloxetine Versus Placebo in the Prevention of Relapse of Major Depressive Disorder
A Clinical Trial of Oral Ganaxolone in Women With Postpartum Depression
Pharmacokinetics and Tolerability of Vortioxetine (Lu AA21004) in Child and Adolescent Patients With Depressive or Anxiety Disorder
An Eight-Week Study Evaluating the Efficacy of Two Fixed Doses (250 mg Twice Daily and 100 mg Twice Daily) of SSR149415 in Patients With Major Depressive Disorder
An Eight-Week Study Evaluating the Efficacy and Tolerability of Two Doses of SSR149415 in Outpatients With Major Depressive Disorder
Study Of 323U66 SR In Major Depressive Disorder
TAK-653 Escalating Single and Multiple Dose Study in Healthy Participants
A PET Study in Healthy Volunteers
Bupropion Hydrochloride 300 mg Extended Release Tablets Under Fasting Conditions
Repeat Dose Study of Controlled-Release Paroxetine Tablets and Immediate-Release Paroxetine Tablets in Healthy Japanese Male Subjects
Paxil CR Bioequivalence Study Brazil - Fed Administration
Paxil CR Bioequivalence Study Brazil
Single Dose Study of Controlled-Release Paroxetine Tablets in Healthy Japanese Male Subjects
Food and Relative Bioavailability Study
GSK372475 PK Study in Healthy Volunteers
PAXIL CR Bioequivalence Study
A Repeat Dose Pharmacokinetic Study Of Paroxetine CR Tablet In Healthy Chinese Subjects
Single Dose Pharmacokinetic (PK) Study Of Paroxetine CR(12.5-37.5mg) In Healthy Chinese Subjects
Seasonal Affective Depression (SAD) Study
Development and Evaluation of a Digital Aftercare Program for Adolescents (12-17 Years) With Depressive Symptoms After Hospital Discharge (Mind-WIN Pilot Study) (Mind-WIN Pilot)
Optimizing tDCS Protocol for Clinical Use in Major Depressive Disorder
Intervention to Prevent Peer Violence & Depressive Symptoms Among At-Risk Adolescents
Collaborative and Stepped Care in Mental Health (COMET)
Telephone-administered Relapse Prevention for Depression
Bupropion & Cardio Birth Defect (Slone)
Bupropion and Specific Cardiovascular Malformations
Carcinogenicity Study of Bupropion
The Effect of Duloxetine on Interoceptive Awareness
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.